Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.63 |
| ▸ | BACE1 | P56817 | 13/20 | 0.59 |
| ▸ | NCK1 | P16333 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 5/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL23412828 | 0.98 | PLAU (0.61) | PLAUBACE1NCK1ESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL23412843 | 0.85 | BACE1 (0.53) | PLAUBACE1NCK1ESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL30074372 | 0.85 | BACE1 (0.53) | PLAUBACE1NCK1ESR1ESR2 | |
| SCHEMBL30499285 | 0.84 | BACE1 (0.57) | PLAUBACE1NCK1ESR2NCF1 | |
| SCHEMBL11973788 | 0.84 | BACE1 (0.57) | PLAUBACE1NCK1ESR2NCF1 | |
| SCHEMBL483970 | 0.78 | ESR2 (0.55) | ESR1ESR2 | |
| SCHEMBL30503638 | 0.77 | PLAU (1.00) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL3412309 | 0.77 | PLAU (1.00) | PLAUBACE1NCK1NCF1NOS2 | |
| SCHEMBL1060994 | 0.77 | ESR2 (0.59) | PLAUESR1ESR2 | |
| SCHEMBL29522954 | 0.77 | ESR2 (0.59) | PLAUESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265677-B1 | CORROSION DETECTION PRODUCT AND METHOD | BATTELLE MEMORIAL INSTITUTE (US) | 2019-05-15 | — | — | EP | claimed |
| EP-1157029-B1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | PENTAPHARM AG (CH) | 2005-12-28 | — | — | EP | claimed |
| EP-1157029-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | Pentapharm AG (CH) | 2001-11-28 | — | — | EP | claimed |
| WO-2000050446-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | PENTAPHARM AG (CH) | 2000-08-31 | — | — | WO | claimed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2021105497-A1 | SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105497-A1 | SMALL-MOLECULE NADPH OXIDASE 2 INHIBITORS | UNIVERSITY OF COPENHAGEN (DK) | 2021-06-03 | — | — | WO | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2014-02-13 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| CN-1918128-A | Fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1157029-B1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | PENTAPHARM AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1157029-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | Pentapharm AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050446-A1 | OLIGOPEPTIDE DERIVATIVES FOR THE ELECTROCHEMICAL MEASUREMENT OF PROTEASE ACTIVITY | PENTAPHARM AG (CH) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | HADHB, HADH, FABP4 | PLAU 4225/4885BACE1 1211/4885NCK1 4440/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | PLAU 1425/4885BACE1 1645/4885NCK1 2501/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | PLAU 3078/4885BACE1 2692/4885NCK1 2601/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | PLAU 3078/4885BACE1 2692/4885NCK1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.